Unicycive Therapeutics, Inc. — Q3 2022 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2022. The company is a clinical-stage biotechnology business developing Renazorb for hyperphosphatemia in chronic kidney disease and UNI-494 for acute kidney injury. It had no product sales; reported revenue was licensing revenue.
Financial results and liquidity
| Metric | Q3 2022 | Nine months 2022 | Comparable 2021 period |
|---|---|---|---|
| Licensing revenue | $0.951 million | $0.951 million | None |
| Research and development expense | $4.803 million | $8.596 million | $3.776 million; $4.719 million |
| General and administrative expense | $1.702 million | $5.082 million | $0.939 million; $1.506 million |
| Operating loss | $5.554 million | $12.727 million | $4.715 million; $6.225 million |
| Net loss | $5.557 million | $12.730 million | $5.201 million; $7.265 million |
| Basic and diluted loss per share | $0.37 | $0.85 | $0.37; $0.69 |
Research-stage operations produced no meaningful operating margin measure in the filing. Nine-month operating cash use was $9.567 million; investing cash use was $0.002 million, with no financing cash inflows. Cash fell from $16.579 million at year-end 2021 to $7.010 million at September 30, 2022.
At September 30, 2022, current assets were $9.962 million and current liabilities $5.522 million, giving working capital of approximately $4.440 million. Total liabilities were $5.551 million, primarily accounts payable, accruals and operating lease liabilities; the filing reports no outstanding convertible notes at period-end. Accumulated deficit was $28.669 million.
Changes versus 2021
- Revenue increased from zero following a July 2022 Renazorb license to Lee’s Pharmaceutical for China, Hong Kong and certain other Asian markets. The company recognized the $0.951 million upfront fee; potential launch milestones of up to $1.0 million and tiered royalties of 7%–10% were excluded from recognized revenue because they remained contingent.
- Q3 operating expenses rose 38% and nine-month expenses rose 120%. Management attributed R&D increases mainly to drug-development costs and labor; G&A increases reflected professional services, personnel, public-company costs and, for the nine-month period, directors’ and officers’ insurance.
- Nine-month net loss increased 75% to $12.730 million, despite licensing revenue, reflecting higher operating expenses. Prior-year other expense included interest and a one-time loss on conversion of convertible notes; those notes converted to equity in the 2021 IPO.
Outlook, risks and unusual items
- Funding and going concern: Management said the company would need funding before the end of Q1 2023 to continue operations and fund planned clinical and regulatory work. The filing states there is substantial doubt about its ability to continue as a going concern for one year after the financial statements became available. Additional financing is uncertain; failure to obtain it could require reduced or delayed development activity.
- Management expects continued losses and increased R&D and G&A spending as programs advance. The filing gives no specific revenue, earnings or cash-flow guidance.
- The Lee’s license generates a sublicense-income obligation to Spectrum: 20% of the upfront payment was accrued as R&D expense. The agreement also includes potential manufacturing and supply arrangements.
- Clinical, regulatory, financing, intellectual-property, vendor, and commercialization risks remain. The company cited possible COVID-19 and climate-related disruption but said their financial effects could not be quantified. No material changes to previously disclosed risk factors were reported.
- Disclosure controls and internal control over financial reporting were ineffective at quarter-end due to a material weakness involving insufficient accounting staffing, review and segregation of duties. No material misstatement of previously issued statements resulted. Remediation plans include hiring accounting personnel and improving controls; completion was expected by the end of 2023.
- The company reported no pending material legal proceedings and no subsequent events.
Investor verification priorities
- Confirm financing plans, actual cash runway and whether capital was obtained before the stated Q1 2023 need.
- Track clinical and regulatory progress, spending and timelines for Renazorb and UNI-494.
- Review performance under the Lee’s license, including milestone conditions, royalties and any manufacturing and supply agreement.
- Assess progress in remediating the material weakness and strengthening financial-reporting controls.
- Monitor operating cash burn, rising payables and accrued development costs, and any new dilution or financing obligations.